PARP1 and neoplasm: Recently, On the selection of PARP inhibitors and overcoming drug resistance in patients with ovarian cancer, patient-derived organoids (PDOs) is established as a promising tumor model, it allows functional testing of biomarkers for predicting response to PARP inhibitors in EOC.